Not recruiting
Registered drug
Study on the Effects of Atacicept in Adults with IgA Nephropathy
Registered drug
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Atacicept
- Sponsor:Vera Therapeutics Inc.
Back to SpainClinical trials in Barcelona – page 247
3 147 clinical trials in Barcelona, Spain across 23 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in SpainEnsayosClinicos.es(opens in a new tab)Barcelona at a glance
3 147
clinical trials
- Research sites23
Not recruiting
Non-small cell lung cancer
Not recruitingStudy Comparing Nivolumab with Ipilimumab or Nivolumab with Chemotherapy to Chemotherapy Alone in Patients with Early Stage Non-Small Cell Lung Cancer
Registered drugNo placebo
Study Comparing Nivolumab with Ipilimumab or Nivolumab with Chemotherapy to Chemotherapy Alone in Patients with Early Stage Non-Small Cell Lung Cancer
Registered drugNo placebo
- Disease:Non-small cell lung cancer
- Substances:CarboplatinCisplatin+8
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Bristol Myers Squibb International Corporation
Not recruiting
COVID-19
Not recruitingStudy on the Effects of S-217622 for Adults Hospitalized with COVID-19
Investigational
Study on the Effects of S-217622 for Adults Hospitalized with COVID-19
Investigational
- Disease:COVID-19
- Substances:(6E)-6-[(6-Chloro-2-Methyl-2H-Indazol-5-Yl)Imino]-3-[(1-Methyl-1H-1,2,4-Triazol-3-Yl)Methyl]-1-[(2,4,5-Trifluorophenyl)Methyl]-1,3,5-Triazinane-2,4-Dione
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:(6E)-6-[(6-Chloro-2-Methyl-2H-Indazol-5-Yl)Imino]-3-[(1-Methyl-1H-1,2,4-Triazol-3-Yl)Methyl]-1-[(2,4,5-Trifluorophenyl)Methyl]-1,3,5-Triazinane-2,4-Dione
- Sponsor:University Of Minnesota
Not recruiting
Pneumonia bacterial
Not recruitingStudy on the Effectiveness and Safety of Imipenem, Cilastatin, and XNW4107 for Adults with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Registered drugNo placebo
Study on the Effectiveness and Safety of Imipenem, Cilastatin, and XNW4107 for Adults with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Registered drugNo placebo
- Disease:Pneumonia bacterial
- Substances:CilastatinImipenem+2
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Cilastatin
- Sponsor:Evopoint Biosciences USA Inc.
Not recruiting
Breast cancer
Not recruitingStudy Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment
Registered drugNo placebo
Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment
Registered drugNo placebo
- Disease:Breast cancer
- Substances:Fulvestrant(3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Fulvestrant
- Sponsor:Pfizer Inc.
Not recruiting
Malignant melanoma
Not recruitingStudy on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma
Registered drug
Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma
Registered drug
- Disease:Malignant melanoma
- Substances:Nivolumab
Countries:Spain
Spain- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Nivolumab
- Sponsor:Bristol-Myers Squibb Services Unlimited Company
Not recruiting
Hidradenitis
Not recruitingStudy on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa
Investigational
Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa
Investigational
- Disease:Hidradenitis
- Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
- Sponsor:Incyte Corp.
Not recruiting
Dermatomyositis
Not recruitingStudy on the Effects of GLPG3667 for Adults with Dermatomyositis
Investigational
Study on the Effects of GLPG3667 for Adults with Dermatomyositis
Investigational
- Disease:Dermatomyositis
- Substances:Glpg3667 Fumarate
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Glpg3667 Fumarate
- Sponsor:Galapagos
Not recruiting
Acute kidney injury
Not recruitingStudy on Ravulizumab for Protecting Chronic Kidney Disease Patients from Acute Kidney Injury After Heart Surgery
Registered drug
Study on Ravulizumab for Protecting Chronic Kidney Disease Patients from Acute Kidney Injury After Heart Surgery
Registered drug
- Disease:Acute kidney injury
- Substances:Ravulizumab
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Ravulizumab
- Sponsor:Alexion Pharmaceuticals Inc.
Not recruiting
Neoplasm
Not recruitingStudy of CFT1946 alone and with trametinib or cetuximab in patients with BRAF-V600 mutant solid tumors who have received standard treatment
Registered drugNo placebo
Study of CFT1946 alone and with trametinib or cetuximab in patients with BRAF-V600 mutant solid tumors who have received standard treatment
Registered drugNo placebo
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Cetuximab
- Sponsor:C4 Therapeutics Inc.
Not recruiting
Prostate cancer metastatic
Not recruitingStudy on Darolutamide and Androgen Deprivation Therapy for Men with Metastatic Hormone-Sensitive Prostate Cancer
Registered drug
Study on Darolutamide and Androgen Deprivation Therapy for Men with Metastatic Hormone-Sensitive Prostate Cancer
Registered drug
- Disease:Prostate cancer metastatic
- Substances:Darolutamide
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Darolutamide
- Sponsor:Bayer AG
Not recruiting
Hormone receptor positive HER2 negative breast cancer
Not recruitingStudy of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer
Registered drugNo placebo
Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer
Registered drugNo placebo
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AbemaciclibCapivasertib+3
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
- Sponsor:AstraZeneca AB
Other cities in Spain
The busiest research cities in the country
- Madrid3 294 trials · 24 research sites
- Valencia1 777 trials · 8 research sites
- Sevilla1 637 trials · 4 research sites
- Malaga1 052 trials · 4 research sites
- L'hospitalet De Llobregat978 trials · 4 research sites
- Badalona768 trials · 3 research sites
- Pamplona753 trials · 1 research site
- Santiago De Compostela682 trials · 3 research sites
Clinical research in Barcelona
What the registry says about research in the country
01 Neurodegenerative Research
Innovative studies focusing on Alzheimer's Disease and Frontotemporal Dementia, utilizing advanced brain imaging techniques to track disease progression and evaluate new therapeutic approaches.
- Cerebral tau aggregates assessment
- Amyloid deposition tracking
- Progressive supranuclear palsy research
Advanced neuroimaging studies using PET tracers to understand disease mechanisms.
02 Infectious Disease Prevention
Comprehensive vaccine trials targeting various infections including Respiratory Syncytial Virus, Cytomegalovirus, and Herpes Zoster.
- RSV vaccine development for older adults
- CMV prevention studies
- COVID-19 booster research
Focus on developing effective immunization strategies for vulnerable populations.
03 Metabolic and Chronic Conditions
Research examining treatments for Type 1 Diabetes and obesity, alongside studies in bladder cancer and urinary tract infections.
- Diabetes management therapies
- Cancer immunotherapy trials
- UTI vaccine development
Innovative approaches to chronic disease management and prevention.